aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Xeno Biosciences, founded to address large unmet needs in metabolic diseases, is a biopharmaceutical company pioneering novel therapeutics. Their core mission is to develop transformational therapies for conditions like obesity, which have limited treatment options beyond bariatric surgery. The company's lead program, XEN-101, is a first-in-class oral formulation designed to shift the gut microbiome to a state associated with weight loss, mimicking the effects of Roux-en-Y gastric bypass surgery. Xeno Biosciences focuses on delivering innovative solutions to improve patient health and quality of life.
The company is led by an experienced team of professionals in the biopharmaceutical industry. Notable investors include prominent venture capital firms specializing in healthcare and biotechnology. Key achievements include advancing XEN-101 through clinical stages, demonstrating its potential to transform the treatment landscape for metabolic diseases. Xeno Biosciences' impact is significant, offering hope for effective, non-surgical interventions for obesity and related metabolic disorders.
Operating Status
Active
Ownership Type(s)
Venture Capital, Equity
Main Product(s)
Therapeutics, Biopharmaceuticals
Technology
Biotech
Tags
Healthtech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Xeno Biosciences founded?
Xeno Biosciences was founded in 2015.
Where is Xeno Biosciences's headquarters located?
Xeno Biosciences's headquarters is located in Cambridge, MA, US.
When was Xeno Biosciences's last funding round?
Xeno Biosciences's most recent funding round was for $1.5M (USD) in January 2023.
How many employees does Xeno Biosciences have?
Xeno Biosciences has 5 employees as of Feb 5, 2024.
How much has Xeno Biosciences raised to-date?
As of July 05, 2023, Xeno Biosciences has raised a total of $8.8M (USD) since Jan 5, 2023.
Add Comparison
Total Raised to Date
$8.8M
USD
Last Update Jan 5, 2023
Last Deal Details
$1.5M
USD
Jan 5, 2023
Debt Financing
Total Employees Over Time
5
As of Feb 2024
Xeno Biosciences Address
1770 Massachusetts Avenue
suite 224
Cambridge,
Massachusetts
02140
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts